National Health (Originator Brand) Amendment Determination 2016 (No. 2) (PB 27 of 2016) (Cth)

PB 27 of 2016

National Health (Originator Brand) Amendment Determination 2016 (No. 2)

National Health Act 1953

I, ADRIANA PLATONA, Assistant Secretary , Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Determination under subsection 99ADB (6B) of the National Health Act 1953.

Dated      30     March 2016

______________________________________

ADRIANA PLATONA
Assistant Secretary
Pharmaceutical Evaluation Branch
Pharmaceutical Benefits Division
Department of Health

1. Name of Determination

   (1)     This Determination is the National Health (Originator Brand) Amendment Determination 2016 (No. 2).

   (2)     This Determination may also be cited as PB 27 of 2016.

2. Commencement

   This Determination commences on 1 April 2016.

3. Amendments to PB 100 of 2015

   Schedule 1 amends the National Health (Originator Brand) Determination 2015 (PB 100 of 2015).

Schedule 1     Amendments

(section 3)

[1]   Schedule 1, table item 21 [entry for baclofen]

Insert as first item, in the columns in the order indicated

Lioresal Intrathecal

[2]   Schedule 1 (after table item 153)

Insert:

153A Modafinil Modavigil